{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:22:55Z","timestamp":1789129375063,"version":"build-2803163510"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":244,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Promedica Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Autologous haematopoietic stem cell transplantation is an effective treatment for aggressive multiple sclerosis refractory to disease-modifying therapies. Yet, its impact on neurodegeneration remains underexplored, and few predictive biomarkers for clinical outcomes after autologous haematopoietic stem cell transplantation exist. We investigated whether autologous haematopoietic stem cell transplantation attenuates retinal neurodegeneration and whether optical coherence tomography-derived retinal measures predict disability progression after transplantation. In this single-centre longitudinal cohort study, optical coherence tomography was performed in people with multiple sclerosis treated with autologous haematopoietic stem cell transplantation and non-transplanted controls with relapsing-remitting multiple sclerosis. Retinal layer atrophy rates pre-transplantation and up to 36 months post-transplantation were estimated using linear mixed-effects models, and post-transplantation rates were compared with those of non-transplanted controls. Cumulative link mixed models were used to assess whether baseline retinal layer thickness predicted clinical progression after transplantation. The autologous haematopoietic stem cell transplantation cohort included 39 participants [23\/39 (59%) female], comprising 23 with relapsing-remitting [15\/23 (65%) female], 8 with secondary progressive [5\/8 (62.5%) female] and 8 with primary progressive multiple sclerosis [3\/8 (37.5%) female]. The relapsing-remitting multiple sclerosis control cohort on disease-modifying treatment included 48 participants [31\/48 (65%) female]. In relapsing-remitting multiple sclerosis, autologous haematopoietic stem cell transplantation reduced thinning of the ganglion cell\/inner plexiform layer by 0.65\u2005\u00b5m\/year (95% CI 0.16 to 1.15, P = 0.010), temporal-quadrant peripapillary retinal-nerve-fibre layer by 1.22\u2005\u00b5m\/year (95% CI 0.63 to 1.81, P &amp;lt; 0.001) and papillomacular bundle peripapillary retinal-nerve-fibre layer by 1.59\u2005\u00b5m\/year (95% CI 0.89 to 2.29, P &amp;lt; 0.001). Post-transplantation atrophy rates of the global, temporal and papillomacular-bundle peripapillary retinal nerve fibre layer were lower in the autologous haematopoietic stem cell transplantation cohort than in the control cohort by 0.275\u2005\u00b5m\/year (95% CI 0.048 to 0.502, P = 0.014), 0.294\u2005\u00b5m\/year (95% CI 0.118 to 0.470, P = 0.001) and 0.200\u2005\u00b5m\/year (95% CI 0.043 to 0.357, P = 0.015), respectively. Higher baseline inner nuclear layer thickness predicted better disability outcomes after transplantation in both relapsing and progressive multiple sclerosis in exploratory statistical models (P &amp;lt; 0.001). In conclusion, retinal optical coherence tomography demonstrated reduced retinal atrophy rates in relapsing-remitting multiple sclerosis after autologous haematopoietic stem cell transplantation. Higher inner nuclear layer thickness before transplantation predicted more favourable neurological outcomes, indicating that the inner nuclear layer, a retinal layer linked to inflammatory multiple sclerosis activity, may help identify patients most likely to benefit from autologous haematopoietic stem cell transplantation.<\/jats:p>","DOI":"10.1093\/braincomms\/fcag336","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:02:09Z","timestamp":1788307329000},"source":"Crossref","is-referenced-by-count":0,"title":["Autologous haematopoietic stem cell transplantation stabilizes retinal atrophy in multiple sclerosis"],"prefix":"10.1093","volume":"8","author":[{"given":"Jay R T","family":"Zoellin","sequence":"first","affiliation":[{"name":"Department of Neurology, University Hospital Zurich , Zurich 8091 ,","place":["Switzerland"]},{"name":"Institute of Molecular and Clinical Ophthalmology Basel (IOB) , Basel 4031 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario E","family":"Mattle","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Zurich , Zurich 8091 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Agostino","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Zurich , Zurich 8091 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne C","family":"Fierz","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Zurich , Zurich 8091 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefine","family":"Ruder","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Zurich , Zurich 8091 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Zaugg","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Zurich , Zurich 8091 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Herwerth","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Zurich , Zurich 8091 ,","place":["Switzerland"]},{"name":"Institute of Pharmacology and Toxicology, University of Zurich , Zurich 8057 ,","place":["Switzerland"]},{"name":"Neuroscience Center Zurich, University of Zurich and ETH Zurich , Zurich 8057 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1748-174X","authenticated-orcid":false,"given":"Michael","family":"Weller","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Zurich , Zurich 8091 ,","place":["Switzerland"]},{"name":"Neuroscience Center Zurich, University of Zurich and ETH Zurich , Zurich 8057 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6387-0714","authenticated-orcid":false,"given":"Shiv","family":"Saidha","sequence":"additional","affiliation":[{"name":"Division of Neuroimmunology and Neurological Infections, Department of Neurology, Johns Hopkins University School of Medicine , Baltimore, MD 21287 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Schippling","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Zurich , Zurich 8091 ,","place":["Switzerland"]},{"name":"Roche Pharma Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center , 4070 Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilijas","family":"Jelcic","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Zurich , Zurich 8091 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3897-214X","authenticated-orcid":false,"given":"Patrick","family":"Roth","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Zurich , Zurich 8091 ,","place":["Switzerland"]},{"name":"Neuroscience Center Zurich, University of Zurich and ETH Zurich , Zurich 8057 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Zurich , Zurich 8091 ,","place":["Switzerland"]},{"name":"Institute of Experimental Immunology, University of Zurich , Zurich 8057 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9362-3156","authenticated-orcid":false,"given":"Veronika","family":"Kana","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Zurich , Zurich 8091 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"issue":"2","key":"2026091107170008600_fcag336-B1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N Engl J Med."},{"issue":"7","key":"2026091107170008600_fcag336-B2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41583-024-00823-z","article-title":"The neuropathobiology of multiple sclerosis","volume":"25","author":"Woo","year":"2024","journal-title":"Nat Rev Neurosci."},{"issue":"3","key":"2026091107170008600_fcag336-B3","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: The 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"issue":"1","key":"2026091107170008600_fcag336-B4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","article-title":"Multiple sclerosis progression: Time for a new mechanism-driven framework","volume":"22","author":"Kuhlmann","year":"2023","journal-title":"Lancet Neurol."},{"issue":"9","key":"2026091107170008600_fcag336-B5","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/brain\/awac016","article-title":"How patients with multiple sclerosis acquire disability","volume":"145","author":"Lublin","year":"2022","journal-title":"Brain."},{"issue":"9","key":"2026091107170008600_fcag336-B6","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol."},{"issue":"10","key":"2026091107170008600_fcag336-B7","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1038\/s41591-025-03901-6","article-title":"AI-driven reclassification of multiple sclerosis progression","volume":"31","author":"Ganjgahi","year":"2025","journal-title":"Nat Med."},{"issue":"12","key":"2026091107170008600_fcag336-B8","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of multiple sclerosis: A review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am J Med."},{"issue":"3","key":"2026091107170008600_fcag336-B9","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41582-024-01050-x","article-title":"Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from ECTRIMS and the EBMT","volume":"21","author":"Muraro","year":"2025","journal-title":"Nat Rev Neurol."},{"issue":"9","key":"2026091107170008600_fcag336-B10","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s11910-023-01290-2","article-title":"Haematopoietic stem cell transplantation for the treatment of multiple sclerosis: Recent advances","volume":"23","author":"Mariottini","year":"2023","journal-title":"Curr Neurol Neurosci Rep."},{"issue":"12","key":"2026091107170008600_fcag336-B11","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16427","article-title":"Exploring the therapeutic potential of autologous hematopoietic stem cell transplantation in progressive multiple sclerosis-a systematic review","volume":"31","author":"Braun","year":"2024","journal-title":"Eur J Neurol."},{"issue":"18","key":"2026091107170008600_fcag336-B12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810946","article-title":"Dynamics of inflammatory and neurodegenerative biomarkers after autologous hematopoietic stem cell transplantation in multiple sclerosis","volume":"23","author":"Ruder","year":"2022","journal-title":"Int J Mol Sci."},{"key":"2026091107170008600_fcag336-B13","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.820256","article-title":"Intermediate-intensity autologous hematopoietic stem cell transplantation reduces serum neurofilament light chains and brain atrophy in aggressive multiple sclerosis","volume":"13","author":"Mariottini","year":"2022","journal-title":"Front Neurol."},{"issue":"Pt 5","key":"2026091107170008600_fcag336-B14","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/brain\/awl370","article-title":"Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis","volume":"130","author":"Metz","year":"2007","journal-title":"Brain."},{"key":"2026091107170008600_fcag336-B15","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104210","article-title":"Biomarkers of demyelination and axonal damage are decreased after autologous hematopoietic stem cell transplantation for multiple sclerosis","volume":"68","author":"Zjukovskaja","year":"2022","journal-title":"Mult Scler Relat Disord."},{"issue":"5","key":"2026091107170008600_fcag336-B16","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/acn3.51045","article-title":"Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis","volume":"7","author":"Thebault","year":"2020","journal-title":"Ann Clin Transl Neurol."},{"issue":"4","key":"2026091107170008600_fcag336-B17","first-page":"643","article-title":"Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation","volume":"75","author":"Inglese","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"2026091107170008600_fcag336-B18","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1177\/1352458516650992","article-title":"Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis","volume":"23","author":"Lee","year":"2017","journal-title":"Multiple Sclerosis"},{"issue":"12","key":"2026091107170008600_fcag336-B19","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1212\/01.wnl.0000219816.44094.f8","article-title":"Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis","volume":"66","author":"Chen","year":"2006","journal-title":"Neurology"},{"key":"2026091107170008600_fcag336-B20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.msard.2018.03.007","article-title":"Optical coherence tomography as a biomarker of neurodegeneration in multiple sclerosis: A review","volume":"22","author":"Alonso","year":"2018","journal-title":"Mult Scler Relat Disord."},{"issue":"7","key":"2026091107170008600_fcag336-B21","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s00415-016-8127-y","article-title":"Timing of retinal neuronal and axonal loss in MS: A longitudinal OCT study","volume":"263","author":"Balk","year":"2016","journal-title":"J Neurol."},{"issue":"9","key":"2026091107170008600_fcag336-B22","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S1474-4422(10)70168-X","article-title":"Optical coherence tomography in multiple sclerosis: A systematic review and meta-analysis","volume":"9","author":"Petzold","year":"2010","journal-title":"Lancet Neurol."},{"issue":"4","key":"2026091107170008600_fcag336-B23","article-title":"Retinal layer thinning is reflecting disability progression independent of relapse activity in multiple sclerosis","volume":"6","author":"Bsteh","year":"2020","journal-title":"Mult Scler J Exp Transl Clin."},{"issue":"5","key":"2026091107170008600_fcag336-B24","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/ana.24487","article-title":"Optical coherence tomography reflects brain atrophy in multiple sclerosis: A four-year study","volume":"78","author":"Saidha","year":"2015","journal-title":"Ann Neurol."},{"issue":"4","key":"2026091107170008600_fcag336-B25","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1007\/s00415-022-11535-8","article-title":"Optical coherence tomography reflects clinically relevant gray matter damage in patients with multiple sclerosis","volume":"270","author":"Cagol","year":"2023","journal-title":"J Neurol."},{"issue":"3","key":"2026091107170008600_fcag336-B26","article-title":"Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study","volume":"5","author":"Balk","year":"2019","journal-title":"Mult Scler J Exp Transl Clin."},{"issue":"6","key":"2026091107170008600_fcag336-B27","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S1474-4422(16)00068-5","article-title":"Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: A cohort study","volume":"15","author":"Martinez-Lapiscina","year":"2016","journal-title":"Lancet Neurol."},{"issue":"6","key":"2026091107170008600_fcag336-B28","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1212\/WNL.0000000000003582","article-title":"Disease-modifying therapies modulate retinal atrophy in multiple sclerosis: A retrospective study","volume":"88","author":"Button","year":"2017","journal-title":"Neurology"},{"issue":"16","key":"2026091107170008600_fcag336-B29","doi-asserted-by":"crossref","first-page":"e2058","DOI":"10.1212\/WNL.0000000000011788","article-title":"Association of spectral-domain OCT with long-term disability worsening in multiple sclerosis","volume":"96","author":"Lambe","year":"2021","journal-title":"Neurology"},{"issue":"11","key":"2026091107170008600_fcag336-B30","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1111\/ene.14421","article-title":"Optical coherence tomography measures correlate with brain and spinal cord atrophy and multiple sclerosis disease-related disability","volume":"27","author":"Vidal-Jordana","year":"2020","journal-title":"Eur J Neurol."},{"issue":"11","key":"2026091107170008600_fcag336-B31","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1093\/brain\/aww219","article-title":"Retinal inner nuclear layer volume reflects response to immunotherapy in multiple sclerosis","volume":"139","author":"Knier","year":"2016","journal-title":"Brain."},{"issue":"11","key":"2026091107170008600_fcag336-B32","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S1474-4422(12)70213-2","article-title":"Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: A retrospective study","volume":"11","author":"Saidha","year":"2012","journal-title":"Lancet Neurol."},{"issue":"20","key":"2026091107170008600_fcag336-B33","doi-asserted-by":"crossref","first-page":"e2525","DOI":"10.1212\/WNL.0000000000011933","article-title":"Modulation of retinal atrophy with rituximab in multiple sclerosis","volume":"96","author":"Lambe","year":"2021","journal-title":"Neurology"},{"issue":"6","key":"2026091107170008600_fcag336-B34","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1111\/ene.14829","article-title":"Retinal layer thinning predicts treatment failure in relapsing multiple sclerosis","volume":"28","author":"Bsteh","year":"2021","journal-title":"Eur J Neurol."},{"issue":"2","key":"2026091107170008600_fcag336-B35","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol."},{"issue":"2","key":"2026091107170008600_fcag336-B36","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"2","key":"2026091107170008600_fcag336-B37","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1212\/NXI.0000000000000671","article-title":"Bilateral retinal pathology following a first-ever clinical episode of autoimmune optic neuritis","volume":"7","author":"Wicki","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"11","key":"2026091107170008600_fcag336-B38","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"2026091107170008600_fcag336-B39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.794077","article-title":"NK cells and innate-like T cells after autologous hematopoietic stem cell transplantation in multiple sclerosis","volume":"12","author":"Ruder","year":"2021","journal-title":"Front Immunol."},{"key":"2026091107170008600_fcag336-B40"},{"key":"2026091107170008600_fcag336-B41","author":"Python Software Foundation"},{"issue":"4","key":"2026091107170008600_fcag336-B42","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0895-4356(00)00314-0","article-title":"Adjusting for multiple testing\u2013when and how?","volume":"54","author":"Bender","year":"2001","journal-title":"J Clin Epidemiol."},{"issue":"9","key":"2026091107170008600_fcag336-B43","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1177\/1352458520964409","article-title":"Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis","volume":"27","author":"Bermel","year":"2021","journal-title":"Mult Scler"},{"key":"2026091107170008600_fcag336-B44","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101414","article-title":"Retinal nerve fiber layer thickness associates with cognitive impairment and physical disability in multiple sclerosis","volume":"36","author":"Birkeldh","year":"2019","journal-title":"Mult Scler Relat Disord."},{"issue":"2","key":"2026091107170008600_fcag336-B45","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1214\/12-STS410","article-title":"Model selection in linear mixed models","volume":"28","author":"M\u00fcller","year":"2013","journal-title":"Stat Sci."},{"issue":"4","key":"2026091107170008600_fcag336-B46","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1214\/12-AOS1028","article-title":"Variable selection in linear mixed effects models","volume":"40","author":"Fan","year":"2012","journal-title":"Ann Stat."},{"issue":"4","key":"2026091107170008600_fcag336-B47","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3758\/s13428-016-0809-y","article-title":"Evaluating significance in linear mixed-effects models in R","volume":"49","author":"Luke","year":"2017","journal-title":"Behav Res Methods."},{"issue":"4","key":"2026091107170008600_fcag336-B48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0034823","article-title":"The OSCAR-IB consensus criteria for retinal OCT quality assessment","volume":"7","author":"Tewarie","year":"2012","journal-title":"PLoS One"},{"issue":"9","key":"2026091107170008600_fcag336-B49","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.3174\/ajnr.A0644","article-title":"A three-year study of brain atrophy after autologous hematopoietic stem cell transplantation in rapidly evolving secondary progressive multiple sclerosis","volume":"28","author":"Rocca","year":"2007","journal-title":"AJNR Am J Neuroradiol."},{"issue":"6","key":"2026091107170008600_fcag336-B50","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1053\/j.semnuclmed.2024.09.007","article-title":"Emerging TSPO-PET radiotracers for imaging neuroinflammation: A critical analysis","volume":"54","author":"Cumbers","year":"2024","journal-title":"Semin Nucl Med."}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcag336\/70896072\/fcag336.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/8\/5\/fcag336\/70896072\/fcag336.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/8\/5\/fcag336\/70896072\/fcag336.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:17:14Z","timestamp":1789125434000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcag336\/8778764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcag336","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"fcag336"}}